Portal de Periódicos da CAPES

Anticoagulation in atrial fibrillation: Special scenarios

2023; GSC Online Press; Volume: 18; Issue: 3 Linguagem: Inglês

10.30574/wjarr.2023.18.3.1187

2581-9615

Erick Alexander Cabrera Estrada, Epitafio Rafael Mestre Sequeda, John Alexander Caballero Ríos, Carlos José Brito Jácome, Olga Virginia Jacquin Serna, Gabriela Lucia Lara Barreto,

Atrial Fibrillation Management and Outcomes

Atrial fibrillation is the most common cardiac arrhythmia in the world, with an estimated prevalence of 2 to 4%, and represents a high burden of disease worldwide. It is defined as a supraventricular tachyarrhythmia with loss of atrial activity, diagnosed by specific electrocardiographic findings. Its classification is clearly defined, based on the form of presentation, duration and the resolution of the episodes. One of the pillars in the treatment of this pathology is anticoagulant therapy, which represents a challenge due to the heterogeneity of the patients, however there are specific situations such as chronic kidney disease, oncological diseases and liver disease, where the situation becomes even more complex, however different studies have been carried out in which the best strategies based on scientific evidence have been proposed for the approach of these patients in special situations.